Robotic retroperitoneal lymph node dissection for testicular cancer: feasibility and latest outcomes.
Publication Title
Current opinion in urology
Document Type
Article
Publication Date
12-24-2018
Abstract
PURPOSE OF REVIEW: Robotic-assisted laparoscopic retroperitoneal lymph node dissection (R-RPLND) is gaining acceptance as an alternative to open and laparoscopic RPLND for the treatment of testicular cancer. We discuss the current state of R-RPLND and summarize the latest relevant literature regarding the feasibility of this operation.
RECENT FINDINGS: R-RPLND has been utilized effectively for both treatment of high-risk, clinical stage I testicular cancer as well as in the postchemotherapy setting. The feasibility of R-RPLND has been established with complication rates comparable to open RPLND and with decreased postoperative hospital stay and blood loss.
SUMMARY: As R-RPLND continues to evolve and experience grows in high-volume centers, more information will be gained regarding long-term oncologic outcomes. Ultimately, head-to-head trials comparing R-RPLND to open RPLND will be needed to determine the role of R-RPLND in the treatment of testicular cancer.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Urology
